Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -69.47% is 63% below its 5-year average of -42.58%, near the low end of its 5-year range (-75.07%–-16.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.24% below its 12-month average of -61.35%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -69.47%.
RETURN ON EQUITY (ROE)
-69.47%
RETURN ON EQUITY (ROE) AVG TTM
-61.35%
RETURN ON EQUITY (ROE) AVG 3Y
-53.47%
RETURN ON EQUITY (ROE) AVG 5Y
-42.58%
RETURN ON EQUITY (ROE) AVG 10Y
-50.50%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-13.24%
CURRENT VS 3Y AVG
-29.93%
CURRENT VS 5Y AVG
-63.16%
CURRENT VS 10Y AVG
-37.57%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-65.36%
vs the sector median at left
Citius Pharmaceuticals, Inc.
Market Cap
$13.20M
Return on Equity (ROE)
-69.47%
TTM Avg
-61.35%
3Y Avg
-53.47%
5Y Avg
-42.58%
Market Cap
$13.33M
Return on Equity (ROE)
-101.66%
TTM Avg
-140.38%
3Y Avg
-131.64%
5Y Avg
-101.94%
Market Cap
$13.48M
Return on Equity (ROE)
-39.76%
TTM Avg
-59.76%
3Y Avg
-51.18%
5Y Avg
-40.48%
Market Cap
$12.79M
Return on Equity (ROE)
N/A
TTM Avg
-162.71%
3Y Avg
-135.96%
5Y Avg
-98.83%
Market Cap
$12.78M
Return on Equity (ROE)
-85.82%
TTM Avg
-222.53%
3Y Avg
-140.00%
5Y Avg
-73.12%
Market Cap
$12.69M
Return on Equity (ROE)
-810.41%
TTM Avg
-174.22%
3Y Avg
-126.94%
5Y Avg
-100.46%
Market Cap
$13.75M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.58M
Return on Equity (ROE)
N/A
TTM Avg
-306.31%
3Y Avg
-229.99%
5Y Avg
-161.76%
Market Cap
$13.86M
Return on Equity (ROE)
-372.67%
TTM Avg
-433.17%
3Y Avg
-292.89%
5Y Avg
-208.82%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $13.20M | -69.47% | -61.35% | -53.47% | -42.58% |
| IN8bio, Inc. (INAB)vs › | $13.33M | -101.66% | -140.38% | -131.64% | -101.94% |
| Optimi Health Corp. (OPTH)vs › | $13.48M | -39.76% | -59.76% | -51.18% | -40.48% |
| Cytosorbents Corporation (CTSO)vs › | $12.79M | N/A | -162.71% | -135.96% | -98.83% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | -85.82% | -222.53% | -140.00% | -73.12% |
| Passage Bio, Inc. (PASG)vs › | $12.69M | -810.41% | -174.22% | -126.94% | -100.46% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | N/A | -306.31% | -229.99% | -161.76% |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | -372.67% | -433.17% | -292.89% | -208.82% |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | N/A | -201.97% | -21.23% | 365.72% |
ROE
-69.5%
ROA
-32.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -69.47% |
| 2026-03-31 | -75.07% |
| 2025-12-31 | -44.88% |
| 2025-09-30 | -55.42% |
| 2025-06-30 | -61.89% |
| 2025-03-31 | -69.32% |
| 2024-12-31 | -60.66% |
| 2024-09-30 | -55.85% |
| 2024-06-30 | -44.69% |
| 2024-03-31 | -45.61% |
| 2023-12-31 | -45.06% |
| 2023-09-30 | -35.83% |
| 2023-06-30 | -31.31% |
| 2023-03-31 | -33.96% |
| 2022-12-31 | -27.89% |
| 2022-09-30 | -32.72% |
| 2022-06-30 | -27.90% |
| 2022-03-31 | -23.45% |
| 2021-12-31 | -19.47% |
| 2021-09-30 | -17.44% |
| 2021-06-30 | -16.25% |
| 2021-03-31 | -16.83% |
| 2020-12-31 | -84.81% |
| 2020-09-30 | -52.12% |
| 2020-06-30 | -59.42% |
| 2020-03-31 | -74.87% |
| 2019-12-31 | -78.57% |
| 2019-09-30 | -63.84% |
| 2019-06-30 | -68.62% |
| 2019-03-31 | -59.28% |
| 2018-12-31 | -54.45% |
| 2018-09-30 | -44.99% |
| 2018-06-30 | -58.85% |
| 2018-03-31 | -55.88% |
| 2017-12-31 | -44.30% |
| 2017-09-30 | -47.32% |
| 2017-06-30 | -85.66% |
| 2017-03-31 | -79.51% |
| 2016-12-31 | -61.01% |
| 2016-09-30 | -49.48% |
| 2016-06-30 | -36.42% |
| 2016-03-31 | -18.72% |
